Objective: Progress in the treatment of multiple sclerosis (MS) has resulted in larger numbers of patients living to an advanced age, but little is known about the cognitive status of these individuals. The primary purpose of this study was to identify differences in the cognitive performance between elderly individuals with MS and those with amnestic mild cognitive impairment (aMCI). Method: Three groups ranging in age from 60 to 80 were compared: patients with MS (n ϭ 64), patients with aMCI (n ϭ 58), and healthy adults (n ϭ 70). All participants completed a standard neuropsychological test battery that evaluated domains of attention, processing speed, executive function, memory, language, and visual spatial function. Results: Compared to age-and gender-matched healthy controls, elderly MS patients exhibited a pattern of cognitive impairment centering on information processing speed and memory that was consistent with the deficits observed in other studies of MS patients regardless of age. Compared to aMCI patients, the MS patients exhibited worse performance on measures of processing speed, but better performance on a measure of memory under cued conditions (Selective Reminding Test), a nonspeeded measure of language (Boston Naming Test), and measures of executive function with processing speed statistically controlled (Trail Making Test, Stroop Test). Conclusions: Differences on neuropsychological measures can serve to distinguish aMCI from MS-related cognitive impairment in older patients, but it is essential that these measures control for the deficit in processing speed that is such a primary feature of MS.
Advances in the treatment of multiple sclerosis (MS) have led to improvements in prognosis and life expectancy (Finlayson, 2009 ) and thus a larger cohort of older individuals with MS. Approximately 9% of MS patients are older than 65 years (Awad & Stüve, 2010) . Cognitive impairment remains one of the least investigated areas in these individuals (Vargas & Arnett, 2014) . Both cross-sectional (Bodling, Denney, & Lynch, 2009; Smestad, Sandvik, Landrø, & Celius, 2010) and longitudinal studies (Amato, Ponziani, Siracusa, & Sorbi, 2001; Bergendal, Fredrikson, & Almkvist, 2007; Schwid, Goodman, Weinstein, McDermott, & Johnson, 2007; Strober, Rao, Lee, Fischer, & Rudick, 2014) show that deficits in cognitive performance worsen over the course of MS. A study of Norwegian patients diagnosed with MS between 1940 and 1980 found that 48% met the investigators' criteria for cognitive impairment after 30 years of disease duration (Smestad et al., 2010) . Longitudinal studies have reported the percentage of patients who shift from an intact to an impaired cognitive profile over a 10-year period ranges from 5% (Schwid et al., 2007) to 30% (Amato et al., 2001) . Other studies report shifts of 18% over 18 years (Strober et al., 2014) and 16% over 8 years (Bergendal et al., 2007) . Comparisons across these studies are complicated by differences in the operational definitions of impairment. However, all confirm that cognitive performance declines in MS patients as they age, and furthermore, that the declines gener-ally occur in the two areas most commonly affected by MS from the outset of the disease, processing speed and memory (Chiaravalloti & DeLuca, 2008; DeLuca, Yates, Beale, & Morrow, 2015) .
An older patient with an existing diagnosis of MS who raises concerns about cognitive function poses a challenge in differentiating these concerns from normal aging, symptoms associated with the established medical history, or, alternatively, the onset of a comorbid dementing condition. Little is known about how the cognitive profile of older patients with MS differs from those of healthy older adults or individuals with mild cognitive impairment. Only one previous study (Müller et al., 2013) bears on this topic. It featured a comparison among patients with secondary progressive MS (SPMS), patients with amnestic mild cognitive impairment (aMCI), and healthy older individuals, with all samples equivalent in age (M ϭ 61). Healthy individuals performed better than both patient groups on all tests comprising the neuropsychological battery. No differences were observed between SPMS and aMCI patients on any measure, except delayed recognition of a word list. On this measure, aMCI patients had significantly lower scores than SPMS patients, whose performance was comparable to that of healthy controls.
The present study is a further attempt to characterize the cognitive profile of older adults with MS using an extensive set of neuropsychological measures. The measures were derived from version 2 of the Uniform Data Set (UDS) neuropsychological test battery (Weintraub et al., 2009 ), a collection of 10 standardized tests used by Alzheimer's Disease Centers across the country. At the site of the present study, the UDS battery was supplemented with four additional tests that were also included in this study. The battery was administered to a sample of older patients with MS, and performance was compared to archival data for a sample of healthy older adults and a sample of aMCI patients. Thus the present study was comparable to the preceding one by Müller et al. (2013) but with a larger, older, and more diverse sample of MS patients consisting of all three major subtypes of MS. We hypothesized that MS patients would show the greatest impairment on tests of processing speed and memory, relative to healthy older adults. Of primary interest, however, were cognitive variables that could distinguish between the MS and aMCI samples. Based on Müller et al.'s findings, we expected to find that aMCI patients differed from MS patients on measures of memory. Some investigators have argued that the memory problems in MS patients involve deficits in retrieval processes rather than acquisition or storage (Chiaravalloti & DeLuca, 2008; DeLuca, Gaudino, Diamond, Christodoulou, & Engel, 1998; Guimarães & Sá, 2012) . On the other hand, aMCI typically involves a broader impairment in memory, encompassing deficits in free and delayed recall (Chen et al., 2000; Tabert et al., 2006) . Although other cognitive abilities are thought to remain basically intact in aMCI (Petersen et al., 2001) , additional deficits have been observed in verbal fluency, object naming, psychomotor speed, visual spatial processing, and attention (Tabert et al., 2006) . Any of these domains might offer measures for distinguishing between aMCI and MS patients.
Method Participants
Sixty-four individuals between the ages of 60 and 80 (M ϭ 66.1; SD ϭ 4.5) who met the revised McDonald criteria for clinically definite MS (Polman et al., 2011) participated in the study. The patients were diagnosed with relapsing (n ϭ 23), primary progressive (n ϭ 19), or secondary progressive MS (n ϭ 22). All were under the care of the same neurologist (Sharon G. Lynch) at the University of Kansas Medical Center. The length of time since being diagnosed with MS ranged from 2 to 47 years (M ϭ 21.2; SD ϭ 11.5). Disability ratings based on the Expanded Disability Status Scale (Kurtzke, 1983) administered by the neurologist at the time of recruitment ranged from 1.0 to 8.0 (Md ϭ 5.0). Eightythree percent of the patients were retired, with half indicating retirement was due to disability. Exclusionary criteria were the following: relapse within the past 3 months; neurological disorder other than MS; history of drug or alcohol abuse; severe visual impairment or no color vision; impairment in the use of their dominant hand; severe cognitive or psychiatric impairment of sufficient magnitude to interfere with the ability to comprehend testing instructions or provide informed consent; or less than a high school education.
The aMCI and healthy control (HC) samples were extracted from archival data collected through the University of Kansas Alzheimer's Disease Center (ADC). Individuals were self-referred to the ADC to participate in longitudinal research on cognition and aging. Individuals completed neuropsychological testing and a Clinical Dementia Rating interview (CDR; Morris, 1993) annually. Based on these results, participants were classified into disease groups via consensus among a neurologist, neuropsychologist, and nurse clinician. A sample of 58 patients classified as aMCI with a CDR of 0.5 on their first visit to the ADC was used in this study. A sample of 70 healthy adults with a CDR of 0 and no evidence of impairment on testing, who met the relevant inclusion/exclusion criteria for the study, was also selected from the ADC database. Ages ranged from 61 to 80 (M ϭ 71.5; SD ϭ 4.9) for the aMCI sample and from 60 to 77 (M ϭ 66.3; SD ϭ 4.5) for the HC sample.
Measures
Cognitive measures were derived from the 10 standardized tests included in version 2 of the UDS (Weintraub et al., 2009 ) and the four supplemental tests used by the local ADC. The supplemental tests were Block Design (Wechsler, 1987) , Letter Number Sequencing (Psychological Corporation, 1997) , the Selective Reminding Test (Buschke, 1984; Grober & Buschke, 1987) , and the Kaplan version of the Stroop Test (Comalli, Wapner, & Werner, 1962; Mitrushina, Boone, Razani, & D'Elia, 2005) . All tests and outcome measures are listed according to their principal cognitive domain in Table 1 . Three derived scores noted in the table warrant further explanation. Scores on both trials of the Category Fluency Test were combined into a single score (CF). Also, proportionate "interference" scores were computed for both the Trail Making Test (Trail-I) and the Stroop Test (Stroop-I) to reflect the extent to which performance on the more complicated trial (Trail-B or color-word naming) was impacted by the additional stimulus burThis document is copyrighted by the American Psychological Association or one of its allied publishers.
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den relative to the simpler trial (Trail-A or color naming). In each instance, the difference between the scores on the two trials was divided by the score on the simpler trial. Interference scores were calculated because previous research within the MS literature suggests failing to control for baseline performance, particularly on measures heavily dependent on processing speed, can lead to the appearance of deficits in higher order skills (e.g., executive function; ). The derived scores replaced some of the original scores used in their computation, and therefore, as noted in Table 1 , the scores for CF-A, CF-V, Trail-B, and Stroop-S were not analyzed in this study. In addition to the cognitive tests, all participants completed the short form of the Geriatric Depression Scale (GDS), a 15-item questionnaire designed for use with older adult populations (Sheikh & Yesavage, 1986) . The scale consists of yes/no questions pertaining to how the individual has felt during the past week.
Procedure
All participants provided signed informed consent for this study. MS patients meeting inclusion and exclusion criteria were introduced to the study during the course of their regular appointment at the MS Clinic. If interest was expressed, a research assistant met with the patient to obtain written consent and schedule an appointment for later testing. The tests were administered in the same order, beginning with the UDS battery followed by the supplemental tests and the GDS. The order of administration for the cognitive tests is indicated in Table 1 . The testing session lasted approximately 60 min.
Statistical Analyses
Data analysis was conducted using IBM SPSS Version 23. Overall group differences were assessed with one-way analyses of variance. Significant findings were then followed by two a priori planned comparisons: MS versus HC and MS versus aMCI. Comparisons between aMCI patients and healthy controls were not considered relevant to this study.
Binary logistic regression was used to identify variables that best differentiated between MS and aMCI patients. The variables consisted of age, gender, depression score, and certain cognitive measures selected on the basis of the univariate comparisons between the two groups. Multicollinearity among these variables was examined using multiple regression. To mitigate suppression effects, variables were entered in the logistic analysis using a backward stepwise method with probabilities of .05 to enter and .10 to remove. The Hosmer and Lemeshow R 2 coefficient (R HL 2 ) served to reflect the accuracy of the final model. Scaled scores were used to investigate patterns of impairment across different cognitive domains for the MS and aMCI samples. The scores from the UDS battery were converted to age-corrected scaled scores (M ϭ 10, SD ϭ 3) using an online calculator that incorporates normative UDS data from a large national sample (Shirk et al., 2011) . Four other normative samples were used to convert the raw scores on the supplemental tests into comparable age-corrected scaled scores (Ivnik et al., 1992 (Ivnik et al., , 1997 Ivnik, Malec, Smith, Tangalos, & Peterson, 1996; Psychological Corporation, 1997) . Impairment was defined as a scaled score of 6 (z-score Ϫ1.33) or lower-thus, approximately 1.5 standard deviations below the normative mean. The number of tests with impaired performance was summed both within and across cognitive domains in order to classify an individual's cognitive status as intact or impaired. Cognitive impairment, at an individual level, was defined as impaired performance on at least one test within two or more This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
cognitive domains. Impairment data was examined using 2 ϫ 2 chi-square analyses with p values based on Fisher's exact test (FET).
Results
Demographic information for the three groups of participants is summarized in Table 2 . The groups did not differ in years of education, and the MS and HC groups did not differ in gender or age. However, the MS group consisted of a larger percentage of females (77%) than the aMCI group (40%), 2 (1) ϭ 17.1, p Ͻ .001, and was also younger (M ϭ 66.1) than the aMCI group (M ϭ 71.5), t(120) ϭ 6.32; p Ͻ .001; d ϭ 1.15. The groups also differed significantly in their scores on the GDS; MS patients endorsed more depressive symptoms than either the HC, t(132) ϭ 5.22; p Ͻ .001; d ϭ 0.93, or aMCI group, t(120) ϭ 2.08; p ϭ .040; d ϭ 0.38. To mitigate these differences between the samples, univariate comparisons between MS and aMCI patients on the cognitive measures were performed with age, gender, and depression scores entered as covariates, and similarly univariate comparisons between MS and HC groups were performed with depression scores entered as a covariate. Before proceeding with each analysis of covariance, the covariates were examined with respect to the assumption of homogeneity of slopes. Six instances of failure to meet this assumption were found. In comparing MS and aMCI groups, heterogeneity of slopes occurred for age on the Stroop-I and for depression scores on the Boston Naming Test and Block Design. In comparing MS and HC groups, heterogeneity of slopes occurred for depression scores on Digit Span Forward and Backward and on Category Fluency. In each of these instances, the heterogeneous covariate was excluded from the analysis of the respective cognitive measure.
Analysis of Cognitive Measures
One member of both the MS and aMCI groups had a few missing data points on cognitive measures (affecting 0.28% of MS and 0.61% of aMCI data). Consequently, some analyses were performed with a slightly smaller sample size than the overall group, as indicated in the body of the results section and in table footnotes. All omnibus analyses examining group differences on cognitive variables were statistically significant. Table 3 lists the results of a priori contrasts between the MS group and the HC or aMCI groups, with group differences in age, gender, and depressive symptoms controlled for through covariance as previously indicated. Significant differences between the MS and HC groups occurred on most of the cognitive measures except for Block Design, Boston Naming Test, Digit Span Backward, Letter Number Sequencing, total recall on the Selective Reminding Task, and the interference scores on the Stroop and the Trail Making Test. In every instance, MS patients performed worse than the HC group. The most robust differences, based on effect sizes, occurred on the Digit-Symbol test (d ϭ 0.74) followed by the memory tests (LM- A binary logistic regression analysis was performed to determine how well the cognitive variables collectively distinguished between the MS and aMCI cohorts and which particular variables were most effective in doing so. The MS sample served as the reference group. The combined sample size exceeded the minimum number recommended by Green for multivariate analyses of this kind (Field, 2009 ). The predictor variables included age, gender, depression scores, and the subset of cognitive variables that fulfilled one of two criteria: (a) the variable significantly distinguished the MS and aMCI groups; or (b) the variable significantly distinguished the MS and HC groups and had a nearsignificant value (p Ͻ .10) for the comparison between the MS and aMCI groups. As noted in Table 3 , this subset consisted of the MMSE, Digit-Symbol, Trail-A and interference score from the Trail Making Test, Stroop-C, and the interference score for the Stroop Test, both recall scores from the Selective Reminding Test, the Boston Naming Test, and Category Fluency. No issues involving multicollinearity were found when this set of predictors was examined using multiple regression. As stated earlier, variables were entered into the logistic regression analysis in a backward stepwise fashion, with probabilities of .05 to enter and .10 to remove.
The results of the analysis are summarized in Table 4 . The resulting model significantly differentiated between MS and aMCI patients ( 2 (7) ϭ 80.7.4, p Ͻ .001, R HL 2 ϭ .514). Fifty-four of 63 This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
MS patients (86%) and 43 of 57 aMCI patients (75%) were correctly classified. When considering the specific predictors retained in the model, three points are important to keep in mind. First, because the MS sample served as the reference group, the B value for each predictor in Table 4 reflects the probability of membership in the aMCI group. Thus, for example, the positive B value for age indicates that the likelihood of being in the aMCI group increased with age. Second, gender was coded with females as the reference value (i.e., F ϭ 0, M ϭ 1); therefore, the positive sign on the B value for gender indicates that the likelihood of membership in the aMCI group was greater for males than for females. Finally, interpretation of the B value for each cognitive variable must take into consideration the direction of the score for that variable. The positive B value for Digit-Symbol indicates the likelihood of membership in the aMCI group increased with better performance on the Digit-Symbol Test; but the positive B value for In addition to analyzing raw scores, performance on each cognitive measure was also converted to an age-corrected scaled score in order to determine impairment in MS and aMCI patients, as described in the Method section. Impairment in two or more domains was the criterion for designating a patient as impaired. The percentage of impaired individuals in the MS and aMCI samples was similar; 36 of 64 (56%) MS patients and 35 of 58 (61%) aMCI patients met this criterion (FET: p ϭ .584).
To determine whether the patterns of impairment differed between the MS and aMCI sample, we examined impairment within each of the six cognitive domains. As described previously, impairment within a particular cognitive domain was defined as approximately 1.5 standard deviations (i.e., a scaled score of 6 or z-score of Ϫ1.33) below the normative mean on at least one measure within the domain. The percentages of impairment in each of the six cognitive domains are presented in Figure 1 . A significantly greater percentage of MS patients than aMCI patients was impaired in the processing speed domain (57% vs. 37%; FET: p ϭ .043). The percentage impairment was higher for MS patients on each of the four measures comprising this domain; however, the difference was only significant in the case of the Stroop-C measure (22% vs. 5%; FET: p ϭ .009) and the Stroop-W measure (24% vs. 9%; FET: p ϭ .030). Conversely, significantly greater percentages of aMCI patients than MS patients were impaired in the memory domain (61% vs. 39%; FET: p ϭ .018) and the language domain (53% vs. 31%; FET: p ϭ .017). The percentage impairment was higher for aMCI patients on each of the measures comprising these domains, but the differences were significant on only the Selective Reminding Test (18% vs. 3%; FET: p ϭ .012) and the Category Fluency Test (52% vs. 31%; FET: p ϭ .027).
Discussion
Cognitive measures successfully distinguished older MS patients from healthy individuals of a comparable age and gender distribution. The most consistent and robust differences between these groups (d ranging from 0.49 to 0.74; This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
SD ϭ .091) and healthy controls (M ϭ .411, SD ϭ .094) is no longer significant, t(131) ϭ 0.99, p ϭ .323, indicating that the original difference on this test may be attributable to processing speed rather than to language skill per se. It is also relevant to note here that the nonspeeded measure within the language domain, the Boston Naming Test, showed no significant difference between MS patients and controls. This pattern of cognitive deficits in processing speed and memory in the present sample of older patients with MS is consistent with that seen in the MS population at large (Benedict et al., 2012; Bobholz & Rao, 2003; Chiaravalloti & DeLuca, 2008; DeLuca et al., 2015; Guimarães & Sá, 2012) . The consistencies are remarkable in their details. For example, with respect to memory, older MS patients differed from healthy controls in their free recall scores on the Logical Memory Test and on the Selective Reminding Test. However, when cues were provided in the latter test, patients' scores improved such that their overall accuracy no longer differed from that of the controls. Similar patterns have been reported in other studies of MS patients' performance on various memory tasks (Rao, Leo, & St. Aubin-Faubert, 1989; DeLuca, Barbieri-Berger, & Johnson, 1994; DeLuca et al., 1998) .
Another example of the consistency with the broader MS population is found in results for the Stroop Test. Several studies have shown that when patients' performance on a set of Stroop stimuli is effectively adjusted for their deficit in processing speed as indicated by their performance on the preliminary color-naming trial, no difference in interference is observed between MS patients and healthy controls (Bodling, Denney, & Lynch, 2008; Denney, Gallagher, & Lynch, 2011; Pujol et al., 2001; van Dijk, Jennekens-Schinkel, Caekebeke, & Zwinderman, 1992) . In the present study, the proportionate interference scores on the Stroop Test confirmed this finding and also showed the same result to be true for the Trail Making Test. Because these two proportionate interference scores were the only measures within the executive function domain of this study, no differences in executive function were evident between MS patients and controls. Previous studies by our group have demonstrated that deficits in executive function are not characteristic of MS. When the test places no burden on processing speed or when processing speed is properly controlled within the measure of executive function, we have shown MS patients perform on a par with healthy individuals (Denney, Hughes, Owens, & Lynch, 2012; Owens, Denney, & Lynch, 2013; Roth, Denney, & Lynch, 2015) . A similar outcome was noted earlier: An apparent difference between MS patients and controls in the language domain was also nullified when scores on the Category Fluency Test were likewise adjusted for processing speed.
The main focus of this study, however, was the comparison between MS and aMCI patients. We used a variety of analyses to examine these differences. On the domain level, individual test scores were converted to age-corrected scaled scores and then combined to determine whether patients were impaired on each of the six domains. This analysis revealed three differences between the MS and aMCI groups. As illustrated in Figure 1 , MS patients were classified as impaired more frequently in the processing speed domain, whereas aMCI patients were classified as impaired more frequently in the memory and language domains.
Univariate comparisons between MS and aMCI patients based on individual test scores were computed with age, gender, and depression scores serving as covariates. MS patients exhibited somewhat poorer performance than aMCI patients on measures of processing speed such as Digit-Symbol, Trail Making Test-A, and the Stroop-color naming trial. Although none of these differences reached significance (p ranging from .067 to .091), they were associated with medium effect sizes (d ranging from 0.31 to 0.33), and, collectively, appear to account for the difference in processing speed noted at the domain level. Significant differences were found on the MMSE, the Boston Naming Test, the interference score on both the Trail Making Test and the Stroop Test, and both scores on the Selective Reminding Test. In each instance, aMCI patients had worse scores than the MS patients.
Given that the aMCI patients were individuals experiencing difficulties with memory, it is perhaps not surprising to find their performance on memory measures to be worse than that of the MS patients. However, as noted earlier, MS patients also had problems with memory when compared to healthy controls. One distinction needs to be highlighted. Although neither group performed on a par with healthy controls on the free recall measure of the Selective Reminding Test, when assistance was provided in the form of cues, MS patients' performance no longer differed from that of controls. Assistance of this kind appears to mitigate memory problems to a greater extent for MS patients than for aMCI patients. Therefore, the more discerning measures of memory for distinguishing aMCI from MS may be those obtained when cues are provided to aid retrieval. This is only a tentative conclusion at present, although it is consistent with the findings reported by Müller and colleagues (2013) . In the present study, the difference between the two groups on the free and cued recall score from the Selective Reminding Test was only moderate (d ϭ 0.49) and was likely compromised by ceiling effects. A total of 78% of the patients (91% MS; 65% aMCI) obtained perfect scores on this measure.
Although Müller et al. (2013) found a difference between aMCI and MS patients on only a single measure of memory, we found differences in measures originating from two additional domains. The interference score on the Trail Making Test reflects the amount of difficulty encountered in alternating between letters and numbers when completing Trail B and is independent of performance on the simpler numerical sequencing task on Trail A. This form of switching is commonly viewed as a type of executive function (Chan, Shum, Toulopoulou, & Chen, 2008; Friedman et al., 2008) . Similarly, the interference score on the Stroop Test reflects the difficulty in deploying attention to the color of the print while avoiding the more automatic response to the printed word itself. Selective attention and inhibition is another commonly agreed upon type of executive function. Whereas MS patients exhibited no difficulty in this domain relative to controls, aMCI patients had significantly greater interference scores on both tests than MS patients.
The aMCI patients also had lower scores than MS patients on the Boston Naming Test, and this was the most robust difference between the two groups of patients (d ϭ 0.51). As a nonspeeded test, the Boston Naming Test is a measure of language skill unaffected by processing speed. When the Category Fluency Test is corrected for processing speed as described earlier, the aMCI group also had significantly lower scores on this measure of language (p ϭ .001, d ϭ 0.60). The present study demonstrates that language skill is an important domain to evaluate when trying This document is copyrighted by the American Psychological Association or one of its allied publishers.
to distinguish aMCI from the cognitive impact of MS, but in doing so, it is essential to avoid measures confounded by processing speed. Separate univariate comparisons fail to take into account interdependence among the various measures. One advantage of multivariate analysis such as the binary logistic regression performed in the present study is that this interdependence is taken into account. Logistic regression also yields an overall model composed of a combination of weighted variables maximized to distinguish between the MS and aMCI groups. The resulting model in the present study accurately distinguished 81% of the patients in the MS and aMCI groups. Part of this accuracy derives from the fact that the aMCI patients tended to be older and more frequently male. Whether these demographic differences constitute a limitation of the study will be considered later. However, even with differences in age and gender accounted for, several cognitive variables contributed significantly to the distinction between the two groups. All of these variables were also identified through the univariate analyses: Digit-Symbol, Boston Naming Test, the interference scores on the Trail Making Test and Stroop Test, and the free and cued recalled score on the Selective Reminding Test. They provide the basis for summarizing the findings of the present study as they relate to the practical issue raised in the introduction, namely that of a clinician confronting an older MS patient with concerns about his or her current cognitive function.
Although unlikely that the resolution regarding these concerns should rest solely on the age and gender of the patient, it is worth noting that the number of MS patients who were male and beyond age 72 was so small that it was impossible to recruit a sample of MS patients that matched the aMCI sample on these demographics. Further, the 3.3:1 female to male gender ratio in the present study is consistent with those reported in the literature (Harbo, Gold, & Tintoré, 2013) . Thus, to the extent that these are population differences, the age and gender of the patient raising concerns over his or her cognitive function are worthy of consideration. Beyond this, the findings of the present study can be encapsulated under four general guidelines pertaining to neuropsychological assessment.
1. Processing speed is seriously compromised in patients with MS, to an even greater extent than in aMCI patients. Therefore, neuropsychological measures used to indicate comorbid aMCI in patients with MS must have minimal loadings on processing speed. If speed is an inherent feature of the test, then some method of adjusting the score for the patient's deficit in processing speed must be employed. We have seen illustrations of this guideline in the contrast between speeded and nonspeeded measures of language and the proportionate interference scores on the Trail Making and Stroop tests. However, the issue is relevant in virtually all neuropsychological assessments of patients with MS. For example, studies have shown that deficits in processing speed can confound the assessment of memory when the items of the test (e.g., words, story elements) are presented too quickly to allow patients an opportunity to process the information with a sufficiency comparable to their peers (Arnett, 2004 Like Müller et al.'s (2013) study, the present study was aligned with a large, multicenter investigation of Alzheimer's disease using a mandated neuropsychological battery explicitly designed to evaluate this form of dementia. Several limitations occurred as a result of this alignment. Because the two studies were aligned with different consortium studies, the batteries used in the studies were not the same. The most obvious deficiency in the present battery was that it had no measure of delayed recognition, the one area in which MS and aMCI patients differed in Müller et al.'s study. Furthermore, in neither of these studies was the battery optimized for individuals with MS. For example, the Symbol Digit Modalities Test is much preferred over Digit-Symbol Test used in the present study because participants are able to respond verbally, and therefore difficulties with manual dexterity frequently found in patients with MS can be avoided. The Trail Making Test is also not typically used with MS patients for the same reason. Fortunately, the Stroop Test, which requires a verbal response, was included as a supplemental test by the local ADC, and scores on the preliminary word reading and color naming trials of this test could be used as suitable measures of processing speed. Finally, it would have been useful to have included a nonspeeded measure of executive function in the battery since, as noted earlier, performance in this domain is another likely candidate for differentiating aMCI from MS patients.
Another potential limitation of the present study is the disparity between the MS and aMCI groups in age, gender, and depression scores. We would argue that, to the extent they reflect true differences between the two patient populations, the disparities are a valid feature of the study design. As previously mentioned, female to male gender ratios ranging between 2:1 and 3:1 are common within MS samples (Harbo et al., 2013) . Similarly, elevated rates of depression, relative to both the general population as well as other chronically ill patient populations, is a common finding in MS (Feinstein, 2011; Patten, Beck, Williams, Barbui, & Metz, 2003; Viner et al., 2014) . Nevertheless, these demographic disparThis document is copyrighted by the American Psychological Association or one of its allied publishers.
ities pose problems when it comes to determining differences between MS and aMCI groups in cognitive performance. Efforts were made to control for these differences in the univariate analysis of the present data, but the application of covariance in such instances is not an ideal solution. Likewise, age, gender, and depression scores were included in the logistic regression analysis, and both age and gender accounted for much of the accuracy in predicting group membership. However, even with statistical controls of this kind imposed on differences between samples of MS and aMCI patients, several cognitive variables contributed significantly to the distinction between the two groups in both the univariate and multivariate analyses. Another less obvious problem stemming from the disparity between the two groups in gender distribution needs to be noted. Normative data stratified by gender was unavailable for some of the measures in the cognitive battery, and therefore only age was considered when determining whether patients were impaired on these measures. As a result, the analysis of impairment within each of the domains does not completely parallel that of the test scores in which both age and gender were controlled. The size of the two samples of patients is also a limitation in this study. Although a sample size exceeding 50 for each group is clearly sufficient for univariate comparisons, larger samples would allow much greater confidence in the reliability of the model emerging from the logistic regression analysis. In the present study, the number of participants barely exceeded the recommended minimums for logistic regression analysis. Also, a larger MS sample would have permitted comparisons between separate subtypes of MS (e.g., relapsing or progressive MS) versus aMCI.
Probably the most important limitation in the design adopted by the present study as well as in the earlier study by Müller et al. (2013) is that it is only indirectly aligned with the ultimate objective of the research. The MS patients in this study were not individuals raising concerns over recent changes in their cognitive status, and therefore, their comparability to the clinical cohort for which the results are intended to generalize is questionable. Nevertheless, the studies yield some indications of the form that cognitive impairment assumes in older individuals with existing diagnoses of MS and how this may differ from that characterizing individuals with aMCI. The differences can then serve to guide clinicians in their efforts to determine the presence of comorbid aMCI in conjunction with MS.
